69957-82-0 Usage
Uses
Used in Organic Synthesis:
(3,4-dichloro-benzyl)-isopropyl-amine is used as a building block in organic synthesis for the preparation of various pharmaceuticals, agrochemicals, and other fine chemicals. Its unique structure and reactivity contribute to the development of complex molecules with potential applications in these fields.
Used in Chemical Research:
In the field of chemical research, (3,4-dichloro-benzyl)-isopropyl-amine serves as a valuable compound for studying its potential biological activity and medicinal properties. Although its specific applications in these areas are still under investigation, its presence in research settings highlights its importance in the advancement of scientific knowledge.
Check Digit Verification of cas no
The CAS Registry Mumber 69957-82-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,9,9,5 and 7 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 69957-82:
(7*6)+(6*9)+(5*9)+(4*5)+(3*7)+(2*8)+(1*2)=200
200 % 10 = 0
So 69957-82-0 is a valid CAS Registry Number.
69957-82-0Relevant academic research and scientific papers
Part 1: Notch-sparing γ-secretase inhibitors: The identification of novel naphthyl and benzofuranyl amide analogs
Lu, Dai,Wei, Han-Xun,Zhang, Jing,Gu, Yongli,Osenkowski, Pamela,Ye, Wenjuan,Selkoe, Dennis J.,Wolfe, Michael S.,Augelli-Szafran, Corinne E.
, p. 2129 - 2132 (2016/04/20)
γ-Secretase is one of two proteases directly involved in the production of the amyloid β-peptide (Aβ), which is pathogenic in Alzheimer's disease. Inhibition of γ-secretase to suppress the production of Aβ should not block processing of one of its alterna
AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS
-
Page/Page column 33, (2010/11/26)
The present invention relates to the CCR3 receptor ligands of the general formula (I), within them favourably to antagonists and to the salts, solvates and isomers thereof, to the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I) and their salts, solvates and isomers and to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers and to the new intermediates of the general formula (IIa).
